<code id='09E32860F6'></code><style id='09E32860F6'></style>
    • <acronym id='09E32860F6'></acronym>
      <center id='09E32860F6'><center id='09E32860F6'><tfoot id='09E32860F6'></tfoot></center><abbr id='09E32860F6'><dir id='09E32860F6'><tfoot id='09E32860F6'></tfoot><noframes id='09E32860F6'>

    • <optgroup id='09E32860F6'><strike id='09E32860F6'><sup id='09E32860F6'></sup></strike><code id='09E32860F6'></code></optgroup>
        1. <b id='09E32860F6'><label id='09E32860F6'><select id='09E32860F6'><dt id='09E32860F6'><span id='09E32860F6'></span></dt></select></label></b><u id='09E32860F6'></u>
          <i id='09E32860F6'><strike id='09E32860F6'><tt id='09E32860F6'><pre id='09E32860F6'></pre></tt></strike></i>

          Home / entertainment / Wikipedia

          Wikipedia


          Wikipedia

          author:explore    Page View:26598
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In